A case of lung adenocarcinoma of the lung with disappearance of brain
metastasis by re-treatment with gefitinib
[Article in Japanese]
Kato
T, Nakashima
M, Yoshimura
K, Imao
M, Goto
H, Yasuda
S, Sano
K.
Respirtory Medicine, National
Hospital
Nagara
Medical
Center.
BACKGROUND: Tumor response rate to gefitinib by previously
treated patients with advanced non-small-cell lung cancer was approximately
20%. However, there are few reports about effect of re-treatment with gefitinib.
CASE: A 40-year-old man was given a diagnosis of adenocarcinoma of lung
(c-T2N3M1). Response was not obtained with chemotherapy (paclitaxel +
carboplatin, vinorelbine + gencitabin). He developed brain metastasis and
received whole brain radiation therapy. He was then given gefitinib. Reduction
of the primary tumor, brain metastasis, pulmonary metastasis and liver
metastasis was seen. Recurrence of pulmonary metastasis and liver metastasis
was discovered 8 months after treatment with gefitinib. Therefore, treatment by
gefitinib was stopped. Response was not achieved with chemotherapy (docetaxel
and amrubicin). At the request of the patient, retreatment with gefitinib was
resumed. Disappearance of brain metastasis was achieved. However, primary tumor,
pulmonary metastasis and liver metastasis progressed. CONCLUSION: We reported a
case whose brain metastases disappeared with re-treatment with gefitinib. This
report is thought to be useful in terms of information about the acquired
resistance of gefitinib. Further investigations are needed to determine the
indication of re-treatment with gefitinib.
一
例肺腺癌并发脑转移, 重用IRESSA后脑转移完全消失的例子
[原文为日文]
加藤 T, Nakashima M, 等
国家医院长良医疗中心,
呼吸医学
.背景:
对以往已治疗过晚期非小细胞肺癌肿瘤,IRESSA反应率为约占20%
. 但是,
只有少数重用IRESSA的报道.
案例:
一个40岁男子被诊断为肺腺癌(C- t2n3m1 ) 化疗没有取得效果 (紫杉醇+卡铂,诺维gencitabin
+ ) . 他发展了脑转移,接受全脑放射治疗.
于是,他被给IRESSA治疗.原发性肿瘤,脑转移,肺转移和肝转移.减少。8个月治疗后,发现肺转移和肝转移复发.
因此,
停止IRESSA治疗. 后来的化疗(紫杉醇amrubicin
)
未取得效果 . 在病人提出要求下,IRESSA被恢复.脑转移达到完全消失. 然而,原发性肿瘤,肺转移和肝转移进展.
结论:
本病例中,重用IRESSA后的脑转移瘤消失,. 这份报告被认为是有用的信息,当IRESSA获得抗药性. 进一步调查后才能确定重用IRESSA的作用范围。.